[HTML][HTML] The Endosomal–Lysosomal Pathway Is Dysregulated by APOE4 Expression in Vivo

T Nuriel, KY Peng, A Ashok, AA Dillman… - Frontiers in …, 2017 - frontiersin.org
T Nuriel, KY Peng, A Ashok, AA Dillman, HY Figueroa, J Apuzzo, J Ambat, E Levy…
Frontiers in neuroscience, 2017frontiersin.org
Possession of the ε4 allele of apolipoprotein E (APOE) is the major genetic risk factor for late-
onset Alzheimer's disease (AD). Although numerous hypotheses have been proposed, the
precise cause of this increased AD risk is not yet known. In order to gain a more
comprehensive understanding of APOE4's role in AD, we performed RNA-sequencing on an
AD-vulnerable vs. an AD-resistant brain region from aged APOE targeted replacement mice.
This transcriptomics analysis revealed a significant enrichment of genes involved in …
Possession of the ε4 allele of apolipoprotein E (APOE) is the major genetic risk factor for late-onset Alzheimer's disease (AD). Although numerous hypotheses have been proposed, the precise cause of this increased AD risk is not yet known. In order to gain a more comprehensive understanding of APOE4's role in AD, we performed RNA-sequencing on an AD-vulnerable vs. an AD-resistant brain region from aged APOE targeted replacement mice. This transcriptomics analysis revealed a significant enrichment of genes involved in endosomal–lysosomal processing, suggesting an APOE4-specific endosomal–lysosomal pathway dysregulation in the brains of APOE4 mice. Further analysis revealed clear differences in the morphology of endosomal–lysosomal compartments, including an age-dependent increase in the number and size of early endosomes in APOE4 mice. These findings directly link the APOE4 genotype to endosomal–lysosomal dysregulation in an in vivo, AD pathology-free setting, which may play a causative role in the increased incidence of AD among APOE4 carriers.
Frontiers